165 related articles for article (PubMed ID: 37391567)
1. Cyclophosphamide in the Treatment of Systemic Lupus Erythematosus-related Guillain-Barré Syndrome: A Systematic Review of Case Reports.
Xiong A; Cui H; Deng R; Wei X
J Neuroimmune Pharmacol; 2023 Sep; 18(3):285-293. PubMed ID: 37391567
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Guillain-Barré Syndrome as Primary Presentation of Systemic Lupus Erythematosus (SLE-GBS) in a Teenage Girl.
Beshir E; Belt E; Chencheri N; Saqib A; Pallavidino M; Terheggen U; Abdalla A; Herlitz L; Sharif E; Bitzan M
Front Pediatr; 2022; 10():838927. PubMed ID: 35372162
[TBL] [Abstract][Full Text] [Related]
3. A Rare Case with Systemic Lupus Erythematosus Manifested by two Different Neurologic Entities; Guillain Barre Syndrome and Posterior Reversible Encephalopathy Syndrome.
Ulutaş F; Çobankara V; Karasu U; Baser N; Akbudak IH
Mediterr J Rheumatol; 2020 Sep; 31(3):358-361. PubMed ID: 33163871
[TBL] [Abstract][Full Text] [Related]
4. A Rare Case of Systemic Lupus Erythematosus With Diffuse Alveolar Hemorrhage and Guillain-Barre Syndrome.
Althagafi ZA; Al-Bishi SS; Ansari R; Alsolami HA; Abdelkader LG
Cureus; 2023 Jan; 15(1):e33984. PubMed ID: 36811038
[TBL] [Abstract][Full Text] [Related]
5. Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis.
Luo W; Mao P; Zhang L; Chen X; Yang Z
Ann Palliat Med; 2020 Mar; 9(2):207-215. PubMed ID: 32156138
[TBL] [Abstract][Full Text] [Related]
6. [A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus].
Shao M; Guo HF; Lei LY; Zhao Q; Ding YJ; Lin J; Wu R; Yu F; Li YC; Miao HL; Zhang LY; DU Y; Jiao RY; Pang LX; Long L; Li ZG; Li R
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1112-1116. PubMed ID: 36533341
[TBL] [Abstract][Full Text] [Related]
7. Systemic lupus erythematosus and guillain-barre syndrome.
Vaidya S; Jasin HE; Logan J
J Clin Rheumatol; 1999 Dec; 5(6):349-53. PubMed ID: 19078429
[TBL] [Abstract][Full Text] [Related]
8. The introspection on the diagnosis and treatment process of a case of Guillain-Barré syndrome (GBS) attributed to systemic lupus erythematosus (SLE): A case report.
Zhang N; Cao J; Zhao M; Sun L
Medicine (Baltimore); 2017 Dec; 96(49):e9037. PubMed ID: 29245299
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis.
Giambalvo S; Garaffoni C; Silvagni E; Furini F; Rizzo R; Govoni M; Bortoluzzi A
Autoimmun Rev; 2022 Apr; 21(4):103038. PubMed ID: 34995765
[TBL] [Abstract][Full Text] [Related]
10. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.
Garnier C; Ribes D; Chauveau D; Huart A; Pugnet G; Adoue D; Prevot G; Alric L; Delobel P; Derumeaux H; Mengelle C; Sailler L; Moulis G
J Rheumatol; 2018 Nov; 45(11):1541-1548. PubMed ID: 30008461
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.
Wolf VL; Taylor EB; Ryan MJ
Physiol Rep; 2019 May; 7(10):e14059. PubMed ID: 31124322
[TBL] [Abstract][Full Text] [Related]
12. Guillain-Barre syndrome as the initial presentation of systemic lupus erythematosus: Case report with a systematic and literature review.
Bhoi SK; Jha M; Jaiswal B
Med J Armed Forces India; 2023 Dec; 79(Suppl 1):S360-S364. PubMed ID: 38144622
[TBL] [Abstract][Full Text] [Related]
13. Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus.
Hussenbocus YAAM; Jin Z; Pan W; Liu L; Wu M; Hu H; Ding X; Wei H; Zou Y; Qian X; Wang M; Wu J; Tao J; Tan J; Da Z; Zhang M; Li J; Feng X; Sun L
Clin Rheumatol; 2022 Jul; 41(7):2043-2052. PubMed ID: 35230560
[TBL] [Abstract][Full Text] [Related]
14. Guillain-Barré syndrome occurring synchronously with systemic lupus erythematosus as initial manifestation treated successfully with low-dose cyclophosphamide.
Ali N; Rampure R; Malik F; Jafri SI; Amberker D
J Community Hosp Intern Med Perspect; 2016; 6(2):30689. PubMed ID: 27124163
[TBL] [Abstract][Full Text] [Related]
15. Severe acute polyradiculoneuritis revealing systemic lupus erythematosus: a case report.
Boudanga A; Chraa M; Rhazouani OC; Kissani N
Pan Afr Med J; 2023; 45():8. PubMed ID: 37346916
[TBL] [Abstract][Full Text] [Related]
16. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic plasma exchange in a patient with acute motor axonal neuropathy subtype of Guillain-Barre syndrome and systemic lupus erythematosus.
Akgun Y; Langlie J; Huberman MA; Wu Y
J Clin Apher; 2022 Aug; 37(4):405-410. PubMed ID: 35218244
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status.
Aceves Avila FJ; Esquivel Nava GA; Gallegos Arreola MP; Gómez Meda B; Zúñiga González G; Ramos-Remus C
J Rheumatol; 2004 Jul; 31(7):1335-9. PubMed ID: 15229952
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports.
Carrillo-Larco RM; Altez-Fernandez C; Ravaglia S; Vizcarra JA
Wellcome Open Res; 2020; 5():107. PubMed ID: 32995555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
